MRK-696

MRK-696 is a **non-selective partial agonist of the benzodiazepine site** on the GABA_A receptor. It modulates GABAergic neurotransmission by binding to the benzodiazepine site but does not fully activate the receptor, distinguishing it pharmacologically from full agonist benzodiazepines such as midazolam and lorazepam. MRK-696 has comparable binding affinity across α1, α2, α3, and α5 GABA_A receptor subtypes, but with partial agonist efficacy. Experimental studies focused on the reinforcing and sedative-motor properties of MRK-696 in animal models, showing reinforcing effects in some but not all contexts, and it produces ataxia and sedation at higher doses. It is a research tool for studying GABA_A receptor subtype pharmacology but is not approved for clinical use[1][3][5][7].

Other names

7-Cyclobutyl-6-(2-methyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(trifluoromethyl)imidazo[1,2-a]pyridine